219 related articles for article (PubMed ID: 29175704)
1. Synthesis and mechanistic investigation of iron(II) complexes of isoniazid and derivatives as a redox-mediated activation strategy for anti-tuberculosis therapy.
Laborde J; Deraeve C; de Mesquita Vieira FG; Sournia-Saquet A; Rechignat L; Villela AD; Abbadi BL; Macchi FS; Pissinate K; Bizarro CV; Machado P; Basso LA; Pratviel G; de França Lopes LG; Sousa EHS; Bernardes-Génisson V
J Inorg Biochem; 2018 Feb; 179():71-81. PubMed ID: 29175704
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity.
Martins F; Santos S; Ventura C; Elvas-Leitão R; Santos L; Vitorino S; Reis M; Miranda V; Correia HF; Aires-de-Sousa J; Kovalishyn V; Latino DA; Ramos J; Viveiros M
Eur J Med Chem; 2014 Jun; 81():119-38. PubMed ID: 24836065
[TBL] [Abstract][Full Text] [Related]
3. Insights on the Mechanism of Action of INH-C
Vila-Viçosa D; Victor BL; Ramos J; Machado D; Viveiros M; Switala J; Loewen PC; Leitão R; Martins F; Machuqueiro M
Mol Pharm; 2017 Dec; 14(12):4597-4605. PubMed ID: 29091448
[TBL] [Abstract][Full Text] [Related]
4. [Fe(CN)5(isoniazid)](3-): an iron isoniazid complex with redox behavior implicated in tuberculosis therapy.
Sousa EH; de Mesquita Vieira FG; Butler JS; Basso LA; Santiago DS; Diógenes IC; Lopes LG; Sadler PJ
J Inorg Biochem; 2014 Nov; 140():236-44. PubMed ID: 25189361
[TBL] [Abstract][Full Text] [Related]
5. Antitubercular activity of Ru (II) isoniazid complexes.
Aguiar Id; Tavares A; Roveda AC; da Silva AC; Marino LB; Lopes ÉO; Pavan FR; Lopes LG; Franco DW
Eur J Pharm Sci; 2015 Apr; 70():45-54. PubMed ID: 25638418
[TBL] [Abstract][Full Text] [Related]
6. New lipophilic isoniazid derivatives and their 1,3,4-oxadiazole analogues: Synthesis, antimycobacterial activity and investigation of their mechanism of action.
Vosátka R; Krátký M; Švarcová M; Janoušek J; Stolaříková J; Madacki J; Huszár S; Mikušová K; Korduláková J; Trejtnar F; Vinšová J
Eur J Med Chem; 2018 May; 151():824-835. PubMed ID: 29679902
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic investigation of the oxidation of hydrazides: implications for the activation of the TB drug isoniazid.
Amos RI; Gourlay BS; Yates BF; Schiesser CH; Lewis TW; Smith JA
Org Biomol Chem; 2013 Jan; 11(1):170-6. PubMed ID: 23165368
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids.
Rodrigues MO; Cantos JB; D'Oca CR; Soares KL; Coelho TS; Piovesan LA; Russowsky D; da Silva PA; D'Oca MG
Bioorg Med Chem; 2013 Nov; 21(22):6910-4. PubMed ID: 24103427
[TBL] [Abstract][Full Text] [Related]
9. Metal complexes of isonicotinylhydrazide and their antitubercular activity.
Ali M; Ahmed M; Hafiz S; Kamal M; Mumtaz M; Hanif M; Khan KM
Pak J Pharm Sci; 2017 Nov; 30(6(Supplementary)):2399-2403. PubMed ID: 29188776
[TBL] [Abstract][Full Text] [Related]
10. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance.
Rawat R; Whitty A; Tonge PJ
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):13881-6. PubMed ID: 14623976
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of enzymatic activities of new KatG mutants from low- and high-level isoniazid-resistant clinical isolates of Mycobacterium tuberculosis.
Brossier F; Boudinet M; Jarlier V; Petrella S; Sougakoff W
Tuberculosis (Edinb); 2016 Sep; 100():15-24. PubMed ID: 27553406
[TBL] [Abstract][Full Text] [Related]
12. Is IQG-607 a Potential Metallodrug or Metallopro-Drug With a Defined Molecular Target in
Abbadi BL; Rodrigues-Junior VDS; Dadda ADS; Pissinate K; Villela AD; Campos MM; Lopes LGF; Bizarro CV; Machado P; Sousa EHS; Basso LA
Front Microbiol; 2018; 9():880. PubMed ID: 29765372
[TBL] [Abstract][Full Text] [Related]
13. Pentacyanoferrate(II) complex of pyridine-4- and pyrazine-2-hydroxamic acid as source of HNO: investigation of anti-tubercular and vasodilation activities.
Carvalho EM; de Freitas Paulo T; Saquet AS; Abbadi BL; Macchi FS; Bizarro CV; de Morais Campos R; Ferreira TLA; do Nascimento NRF; Lopes LGF; Chauvin R; Sousa EHS; Bernardes-Génisson V
J Biol Inorg Chem; 2020 Sep; 25(6):887-901. PubMed ID: 32728907
[TBL] [Abstract][Full Text] [Related]
14. Eosinophil peroxidase oxidizes isoniazid to form the active metabolite against M. tuberculosis, isoniazid-NAD
Babu D; Morgan AG; Reiz B; Whittal RM; Almas S; Lacy P; Siraki AG
Chem Biol Interact; 2019 May; 305():48-53. PubMed ID: 30922765
[TBL] [Abstract][Full Text] [Related]
15. Designing new antitubercular isoniazid derivatives with improved reactivity and membrane trafficking abilities.
de Faria CF; Moreira T; Lopes P; Costa H; Krewall JR; Barton CM; Santos S; Goodwin D; Machado D; Viveiros M; Machuqueiro M; Martins F
Biomed Pharmacother; 2021 Dec; 144():112362. PubMed ID: 34710838
[TBL] [Abstract][Full Text] [Related]
16. A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct.
Mahapatra S; Woolhiser LK; Lenaerts AJ; Johnson JL; Eisenach KD; Joloba ML; Boom WH; Belisle JT
Antimicrob Agents Chemother; 2012 Jan; 56(1):28-35. PubMed ID: 22037847
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of isoniazid by neutrophil myeloperoxidase leads to isoniazid-NAD(+) adduct formation: A comparison of the reactivity of isoniazid with its known human metabolites.
Khan SR; Morgan AG; Michail K; Srivastava N; Whittal RM; Aljuhani N; Siraki AG
Biochem Pharmacol; 2016 Apr; 106():46-55. PubMed ID: 26867495
[TBL] [Abstract][Full Text] [Related]
18. [The mechanism of action of isoniazid. A chemical model of activation].
Bernadou J; Nguyen M; Meunier B
Ann Pharm Fr; 2001 Sep; 59(5):331-7. PubMed ID: 11787427
[TBL] [Abstract][Full Text] [Related]
19. Isoniazid metal complex reactivity and insights for a novel anti-tuberculosis drug design.
Sousa EH; Basso LA; Santos DS; Diógenes IC; Longhinotti E; Lopes LG; Moreira Ide S
J Biol Inorg Chem; 2012 Feb; 17(2):275-83. PubMed ID: 21952749
[TBL] [Abstract][Full Text] [Related]
20. Conformational changes in 2-trans-enoyl-ACP (CoA) reductase (InhA) from M. tuberculosis induced by an inorganic complex: a molecular dynamics simulation study.
da Costa AL; Pauli I; Dorn M; Schroeder EK; Zhan CG; de Souza ON
J Mol Model; 2012 May; 18(5):1779-90. PubMed ID: 21833828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
